← Leaderboards
Susan Halabi
University Of California, San Francisco
$7,630,539
Attributed
$22,790,940
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.2M · FY2011–25$10M$7.5M$5M$2.5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
FDA$11,938,938 · 1
NIH$10,852,002 · 8
By mechanism
U01$14,472,870 · 2
R01$6,152,476 · 3
UH3$1,011,140 · 1
R21$802,846 · 2
UH2$351,608 · 1
Top collaborators
- Andrew J Armstrong10 shared
- Robert John Mentz10 shared
- Ehsan Samei10 shared
- Paul B Watkins10 shared
- Scott M. Dehm5 shared
- Martin Edwin Gleave5 shared
- Joshua Michael Lang5 shared
- Dana Rathkopf5 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Li Zhang$2,842,621
- Sabine Mueller$1,826,791
- Elizabeth McCarthy$184,167
- Electron Kebebew$690,672
- Emily A Hammad Mrig$410,836
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsTumorFutureMalignant Neoplasm Of ProstatePrognosticChemotherapyResponseBiological MarkersResistanceAndrogensDesignRandomizedAbirateroneTargeted TreatmentValidationAcetatesAndrogen ReceptorBiologyProspectiveGeneticProgression-Free SurvivalsVariantEnsureEnrollment
Grant awards (37)
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC$647,291
R01 · FY2025 · CA · contact PI
Research Triangle Center of Excellence in Regulatory Science and Innovation$525,000
U01 · FY2025 · FD
Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$328,747
UH3 · FY2025 · CA
Research Triangle Center of Excellence in Regulatory Science and Innovation$2,033,969
U01 · FY2024 · FD
Research Triangle Center of Excellence in Regulatory Science and Innovation$949,206
U01 · FY2024 · FD
Research Triangle Center of Excellence in Regulatory Science and Innovation$867,730
U01 · FY2024 · FD
Research Triangle Center of Excellence in Regulatory Science and Innovation$750,000
U01 · FY2024 · FD
Research Triangle Center of Excellence in Regulatory Science and Innovation$668,333
U01 · FY2024 · FD
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC$612,180
R01 · FY2024 · CA · contact PI
Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate Cancer$523,041
R01 · FY2024 · CA · contact PI
Research Triangle Center of Excellence in Regulatory Science and Innovation$454,318
U01 · FY2024 · FD
Research Triangle Center of Excellence in Regulatory Science and Innovation$450,533
U01 · FY2024 · FD
Research Triangle Center of Excellence in Regulatory Science and Innovation$376,307
U01 · FY2024 · FD
Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$318,930
UH3 · FY2024 · CA
Sieve based full likelihood approach for the Cox proportional hazards model with applications to immunotherapies trials$178,760
R21 · FY2024 · CA
Research Triangle Center of Excellence in Regulatory Science and Innovation$4,863,542
U01 · FY2023 · FD
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC$636,857
R01 · FY2023 · CA · contact PI
Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate Cancer$466,468
R01 · FY2023 · CA · contact PI
Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$363,463
UH3 · FY2023 · CA
Sieve based full likelihood approach for the Cox proportional hazards model with applications to immunotherapies trials$225,803
R21 · FY2023 · CA
Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate Cancer$640,563
R01 · FY2022 · CA
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC$632,590
R01 · FY2022 · CA · contact PI
Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$160,240
UH2 · FY2022 · CA
Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate Cancer$426,729
R01 · FY2021 · CA
Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$191,368
UH2 · FY2021 · CA
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC$653,173
R01 · FY2020 · CA · contact PI
Serum Androgens as Predictors of Survival in Metastatic Prostate Cancer$207,124
R21 · FY2016 · CA
Validation of prognostic and pathway signatures in lethal prostate cancer$454,043
U01 · FY2015 · CA · contact PI
Serum Androgens as Predictors of Survival in Metastatic Prostate Cancer$191,159
R21 · FY2015 · CA
Validation of prognostic and pathway signatures in lethal prostate cancer$440,421
U01 · FY2014 · CA · contact PI
Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate$231,586
R01 · FY2014 · CA · contact PI
Validation of prognostic and pathway signatures in lethal prostate cancer$511,043
U01 · FY2013 · CA · contact PI
Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate$224,425
R01 · FY2013 · CA · contact PI
Validation of prognostic and pathway signatures in lethal prostate cancer$525,083
U01 · FY2012 · CA
Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate$242,310
R01 · FY2012 · CA · contact PI
Validation of prognostic and pathway signatures in lethal prostate cancer$603,342
U01 · FY2011 · CA
Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate$215,263
R01 · FY2011 · CA · contact PI